FeesSafety
Pluang+
Home/News Feed/Absci reports Q3 2026 results; interim data for hair loss drug ABS-201 expected in December
ABSI
$9.63
-$0.49 -4.84%

Absci reports Q3 2026 results; interim data for hair loss drug ABS-201 expected in December

Company Fundamentals
12 Nov 2026, 14:05 WIB
GlobeNewsWire
View Source
Bullish
Absci reports Q3 2026 results; interim data for hair loss drug ABS-201 expected in December

Absci Corporation announced its Q3 2026 financial results, reporting a net loss of $33.3 million and revenues of $0.3 million. The company is progressing with its ABS-201 drug for pattern hair loss, expecting interim proof-of-concept data in December 2026 and full data in early 2027. Absci also plans to start a Phase 2 trial for ABS-201 in endometriosis in mid-2027. Additionally, the company appointed Gerry Muhle as Chief Commercial Officer to support commercial growth.

Absci Corporation's stock is currently priced at USD 9.90 on Pluang, down 2.17% in the past day. As of Nov 12, 2026 19:12 WIB, the company's market cap stands at $1.73 billion with a trading volume of 5,378,419 shares.

More News (ABSI)

Absci names Gerry Muhle as Chief Commercial Officer to lead ABS-201 and pipeline commercial strategies

Absci names Gerry Muhle as Chief Commercial Officer to lead ABS-201 and pipeline commercial strategies

Absci Corporation appointed Gerry Muhle as Chief Commercial Officer to lead commercial strategies for its ABS-201 hair regrowth treatment and broader pipeline. Muhle brings over 25 years of experience launching prescription biologics and consumer bra...

Market News
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App